摘要
目的观察凝血因子对米非司酮治疗子宫肌瘤效果的影响。方法选择我院2017年10月至2018年10月就诊的子宫肌瘤患者60例,采用米非司酮治疗,按治疗效果分成有效组与无效组,同期健康体检患者30例女性作为正常值参考组,分别检测外周血凝血因子血栓素A2(TXA2)、前列腺素I2(PGI2)、组织纤维蛋白溶酶原激活剂(tPA)、纤溶酶原激活物抑制剂(PAI)、凝血酶时间(TT)、纤维蛋白原(FIB)、血浆凝血酶原时间(PT)、活化部分凝血激酶时间(APTT)、D二聚体(D-dimer),比较有效组与无效组患者外周血各凝血因子水平的差异。采用5分制症状评分评价有效组与无效组患者治疗后症状评分的差异。结果治疗后有效组患者外周血凝血因子TXA2、PGI2、tPA、PAI、TT、FIB、PT、APTT、D二聚体检测结果均优于无效组,差异有统计学意义(P<0.05)。治疗后有效组患者症状评分明显低于无效组,差异有统计学意义(P<0.01)。结论子宫肌瘤患者血TXA2、PGI2、tPA、PAI、TT、FIB、PT、APTT、D二聚体水平与正常妇女比较有异常表达,且对米非司酮治疗子宫肌瘤效果有一定的影响。
Objective To observe the effect of coagulation factor on the treatment of uterine leiomyoma with mifepristone.Methods Sixty cases of uterine leiomyoma in our hospital from October 2017 to October 2018,with mifepristone,it is divided into effective group and ineffective group according to the therapeutic effect,in the same period,30 women were taken as normal reference group,peripheral blood coagulation factor thromboxane A2(TXA2),prostaglandin I2(PGI2),tissue fibrinolysin activator(tPA),plasminogen activator inhibitor(PAI),thrombin time(TT),fibrinogen(FIB),plasma prothrombin time(PT),activated partial thrombokinase time(APTT),and D-dimer comparing the difference of these coagulation factors in peripheral blood between the effective group and the ineffective group.The difference of symptom score between effective group and ineffective group was evaluated by 5-point symptom score.Results After treatment,the detection results of peripheral blood coagulation factors TXA2,PGI2,tPA,PAI,TT,FIB,PT,APTT,D-dimer in the effective group were better than those in the ineffective group,and the difference was statistically significant(P<0.05).After treatment,the symptom score of patients in the effective group was significantly lower than that in the ineffective group,and the difference was statistically significant(P<0.01).Conclusion The level of homodimer in patients with uterine leiomyoma is abnormal compared with that of normal women,and it has a certain effect on the treatment of uterine leiomyoma with mifepristone.
作者
魏芳芳
WEI Fangfang(People's Hospital of Guangchang County,Fuzhou 344900,China)
出处
《中国医药指南》
2020年第33期1-2,5,共3页
Guide of China Medicine
基金
江西省卫计委普通科技计划项目(20197559)。
关键词
子宫肌瘤
凝血因子
米非司酮
Uterine leiomyoma
Coagulation factor
Mifepristone